Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Unknown | 2 |
Target |
Mechanism A2bR antagonists |
Active Org. Tarus Therapeutics, Inc.Startup [+2] |
Originator Org. Tarus Therapeutics, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A2bR antagonists |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JAK1 inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date- |
Sponsor / Collaborator |
Start Date06 Dec 2018 |
Sponsor / Collaborator Tata Chemicals Ltd. [+1] |
Start Date04 Mar 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GKM-001 ( glucokinase ) | Diabetes Mellitus, Type 2 More | Phase 1 |
PNQ-849 ( BTK ) | Autoimmune Diseases More | IND Application |
PNQ-201 ( A2bR ) | Colitis More | IND Application |
PNQ-154 ( BTK C481S ) | Neoplasms More | IND Application |
PNQ-701 ( JAK1 ) | Rheumatoid Arthritis More | IND Application |